Siglec-3

Siglec-3 분자 정보

영어 이름Myeloid cell surface antigen CD33시판 약물 수1
임상 약물 수44표적 별명Myeloid Cell Surface Antigen CD33,CD33 Molecule Transcript,CD33 Antigen,Siglec-3,P67,FLJ00391,Sialic acid-binding Ig-like lectin 3,CD33,CD33 Molecule,CD33 Antigen (Gp67),SIGLEC3,Gp67,Sialic Acid Binding Ig-Like Lectin 3
최고 연구 개발 단계Approved
영어 이름Myeloid cell surface antigen CD33
표적 별명Myeloid Cell Surface Antigen CD33,CD33 Molecule Transcript,CD33 Antigen,Siglec-3,P67,FLJ00391,Sialic acid-binding Ig-like lectin 3,CD33,CD33 Molecule,CD33 Antigen (Gp67),SIGLEC3,Gp67,Sialic Acid Binding Ig-Like Lectin 3
시판 약물 수1
임상 약물 수44
최고 연구 개발 단계Approved

Siglec-3 제품 목록

  • 속성

    Protein (17)Beads (1)

  • 제품 라이브러리

    온라인 (18)

  • Human (15)Cynomolgus (1)Mouse (1)Rat (1)

  • 태그

    His Tag (9)Fc Tag (4)His Tag & Avi Tag (2)- (1)Fc Tag & Avi Tag (1)Llama IgG Fc Tag (1)

  • 마커

    Unconjugated (8)Biotin-labeled (3)FITC Labeled (2)- (1)PE Labeled (2)AF647 Labeled (1)APC Labeled (1)

Siglec-3분자 배경

Myeloid cell surface antigen CD33 is also known as SIGLEC3, Siglecs (sialic acid binding Ig­like lectins) and GP67, is a single-pass type I membrane protein which belongs to the immunoglobulin superfamily and SIGLEC (sialic acid binding Ig-like lectin) family. Human CD33 / Siglec-3 cDNA encodes a 364 amino acid (aa) polypeptide with a hydrophobic signal peptide, an N-­terminal Ig-­like V­-type domain, one Ig­-like C2-­type domains, a transmembrane region and a cytoplasmic tail. CD33 / Siglec-3 usually considered myeloid-specific, but it can also be found on some lymphoid cells. In the immune response, CD33 / Siglec-3 may act as an inhibitory receptor upon ligand induced tyrosine phosphorylation by recruiting cytoplasmic phosphatase(s) via their SH2 domain(s) that block signal transduction through dephosphorylation of signaling molecules. CD33 / Siglec-3 induces apoptosis in acute myeloid leukemia.

Siglec-3분자 별명

CD33,SIGLEC3,gp67

임상 약물 정보

영어 이름연구 코드연구 개발 단계회사적응증임상 시험
BL-M11D1BL-M11D1Phase 3 ClinicalBaili-Bio (Chengdu) Pharmaceutical Co Ltd, Sichuan Baili Pharmaceutical Co LtdLeukemia, Myeloid, Acute; Myelodysplastic Syndromes
상세
BI-836858BI-836858Phase 2 ClinicalC.H. Boehringer Sohn Ag & Co. KgLeukemia, Myeloid, Acute; Myelodysplastic Syndromes
상세
CART-33 (Chinese PLA General Hospital)Phase 2 ClinicalPla General HospitalLeukemia, Myeloid; Leukemia, Myeloid, Acute
상세
Lintuzumab Ac-225AC225-MOAB-M195; HuM195-Ac-225; 225Ac-HuM-195Phase 2 ClinicalPdl Biopharma IncGlioblastoma; Glioma; Gliosarcoma; Leukemia, Myeloid, Acute; Multiple Myeloma
상세
CLL1/CD33/CD38/CD7 CAR-T cell therapyPhase 2 ClinicalGuangzhou Bio-Gene Technology Co LtdLeukemia, Myeloid, Acute
상세
Universal donor derived CD33 CAR-NK cell therapy (Nationwide Children'S Hospital)Phase 2 ClinicalNationwide Children'S HospitalLeukemia, Myeloid, Acute
상세
CD33-CD123-CLL1 CART-T cell therapy (Hebei Taihe Chunyu Biotechnology)Phase 2 ClinicalHebei Tahoe Chunyu Biotechnology Co LtdLeukemia, Myeloid
상세
VBP-301VBP301; VBP-301Phase 2 ClinicalVor Biopharma IncLeukemia, Myeloid, Acute
상세
VBP-101VBP101; VBP-101Phase 2 ClinicalVor Biopharma IncLeukemia, Myeloid, Acute; Myelodysplastic Syndromes
상세
CAR-T Cells Targeting CD33/CD123 therapy(Essen Biotech)BAH244; BAH-244Phase 2 ClinicalEssen BiotechLeukemia, Myeloid, Acute
상세
MP0533MP0533Phase 2 ClinicalMolecular Partners AgLeukemia, Myeloid, Acute
상세
CD33 CAR T Cells(Beijing Boren Hospital)Phase 2 ClinicalBeijing Gao Boren Hospital Co LtdLeukemia; Leukemia, Myeloid, Acute; Neoplasms
상세
EmerfetamabAMG-673; AMG673Phase 1 ClinicalAmgen IncLeukemia, Myeloid, Acute
상세
ICG-136ICG-136; 123b-33bcCARPhase 1 ClinicalIcell Gene Therapeutics (Int'L) LtdLeukemia, Myeloid, Acute
상세
AL-003AL-003Phase 1 ClinicalAbbvie Inc, Alector IncAlzheimer Disease
상세
PRGN-3006PRGN-3006; PRGN-3006 UltraCAR-TPhase 1 ClinicalPrecigen IncLeukemia, Myeloid, Acute; Myelodysplastic Syndromes
상세
anti-CD33 (FL-33) CAR T-cell therapy (Beijing GoBroad Hospital)Phase 1 ClinicalBeijing Gao Boren Hospital Co LtdLeukemia, Myeloid, Acute
상세
anti-CD33/anti-CLL-1 CAR T-cell therapy (Nanjing Legend Biotech)Phase 1 ClinicalLeukemia, Myeloid, Acute
상세
ORM-6151ORM-6151; BMS-986497Phase 1 ClinicalOrum Therapeutics IncLeukemia, Myeloid, Acute; Myelodysplastic Syndromes
상세
SENTI-202SENTI-202Phase 1 ClinicalSenti Biosciences IncHematologic Neoplasms; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes
상세
CD33Bi FPBMC (University Of Virginia)Phase 1 ClinicalUniversity Of VirginiaLeukemia, Myeloid, Acute; Myelodysplastic Syndromes; Myelodysplastic-Myeloproliferative Diseases
상세
A-CAR028A-CAR028Phase 1 ClinicalCellular Biomedicine (Shanghai) Co LtdLeukemia, Myeloid, Acute
상세
ACLX-004ACLX-004Phase 1 ClinicalArcellx IncLeukemia, Myeloid, Acute; Myelodysplastic Syndromes
상세
JNJ-89853413JNJ-89853413Phase 1 ClinicalJanssen Research & Development LlcLeukemia, Myeloid, Acute; Myelodysplastic Syndromes
상세
GTB-3650GTB-3650; GTB-360; OXS-3350; OXS-C3550Phase 1 ClinicalMasonic Cancer Center, University Of MinnesotaBone Marrow Neoplasms; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes
상세
RJK-RT2831RJK-RT2831; RJKRT2831; RT-2831; RT2831Phase 1 ClinicalNanjing RegeneCore Biotech Co LtdHematologic Neoplasms
상세
JNJ-67571244JNJ-1244; JNJ-67571244; JNJ-67371244Phase 1 ClinicalJohnson & JohnsonLeukemia, Myeloid, Acute; Myelodysplastic Syndromes
상세
CD33-NKECD33-NKEPhase 1 ClinicalBristol-Myers Squibb CompanyLeukemia, Myeloid, Acute
상세
Optimised CD33 (FL-33) CAR T Therapy(Beijing GoBroad Hospital)Phase 1 ClinicalBeijing GoBroad HospitalLeukemia, Myeloid, Acute
상세
Universal CAR-T Cells therapy(Shenzhen Geno-Immune Medical Institute)Phase 1 ClinicalShenzhen Geno-Immune Medical InstituteLeukemia, Myeloid, Acute
상세
CD33/CLL1 dual CAR-NK cell therapy (Hangzhou Qihan)Phase 1 ClinicalHangzhou Qihan Biotechnology Co LtdLeukemia, Myeloid, Acute; Neoplasm, Residual
상세
CD33 CAR-NK cell therapy (Hangzhou Qihan)Phase 1 ClinicalHangzhou Qihan Biotechnology Co LtdLeukemia, Myeloid, Acute; Neoplasm, Residual
상세
EluvixtamabAMG-330; MT-114Phase 1 ClinicalAmgen IncLeukemia, Myeloid, Acute; Myelodysplastic Syndromes
상세
IBR-733IBR-733; IBR733Phase 1 ClinicalImbioray (Hangzhou) Biomedicine Co LtdLeukemia, Myeloid, Acute
상세
Anti-CD33 chimeric antigen receptor T cell therapy (Shanghai YaKe/Zhejiang University)Phase 1 ClinicalShanghai YaKe Biotechnology Co LtdLeukemia, Myeloid, Acute
상세
CLL1+CD33 CAR-T(Zhejiang University)Phase 1 ClinicalZhejiang UniversityLeukemia, Myeloid, Acute
상세
anti-CD33 CAR T cells therapy(iCell Gene Therapeutics)Phase 1 ClinicalIcell Gene Therapeutics (Int'L) LtdHematologic Neoplasms; Leukemia, Myeloid, Acute
상세
Lintuzumab Ac-225/VenetoclaxPhase 1 ClinicalActinium Pharmaceuticals IncLeukemia, Promyelocytic, Acute
상세
SC-DARIC33SC-DARIC33; DARIC-33Phase 1 ClinicalGenetix Biotherapeutics IncLeukemia, Myeloid, Acute
상세
DXC-007DXC-007Phase 1 ClinicalHangzhou Dac Biotech Company LtdLeukemia; Leukemia, Myeloid, Acute
상세
Lintuzumab-gelonin conjugatePhase 1 ClinicalThe University Of Texas MD Anderson Cancer CenterLeukemia, Myelogenous, Chronic; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes
상세
Anti-CD33/CLL-1 CAR-T (Legend)Phase 1 ClinicalLegend Biotech CorpLeukemia, Promyelocytic, Acute
상세
Anti-CD33/anti-FcgammaRI bispecific antibody (UCSD)Phase 1 ClinicalUniversity Of California San DiegoLeukemia, Myeloid, Acute
상세
Anti-CD33 CAR T cell therapy (Wuhan Bio-Raid)ClinicalWuhan BioRaid Biotechnology Co LtdLeukemia, Myeloid, Acute
상세

시판 약물 정보

영어 이름연구 코드연구 개발 단계회사가장 빠른 브랜드 이름가장 빠른 승인 국가가장 빠른 적응증가장 빠른 승인 회사가장 빠른 승인 날짜적응증임상 시험
Gemtuzumab ozogamicinCMA-676; CDP-771; WAY-CMA-676; CL-555201; hP67.6-calicheamicinApprovedPfizer Inc, Ucb SaMylotargJapanLeukemia, Myeloid, AcutePfizer Inc2008-01-18Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Juvenile; Myelodysplastic Syndromes
상세

제품 리뷰

  • K***n2023-05-06
    0사람들이 좋아합니다
    While transducing primary cells, I was running into a staining issue with biotinylated-rCD33. A colleague of mine had used rCD33 labelled with PE before and had success with a similar experiment. I decided to order from Acrobio Systems due to the recommendations and high praise from several colleagues. Upon staining, I saw great fluorescence, increased events caught, and higher transduction efficiencies. I will definitely be using this product again!
  • E***g2023-01-18
    4사람들이 좋아합니다
    We purchased this reagent for use in detecting CD33 CAR expression and it worked as advertised. The PE signal gave great separation by flow cytometry and allowed for the clear detection of CAR expression on the surface of our cells. The product page states that the CD33 PE reagent is incompatible with streptavidin-biotin detection systems. When we tried to co-stain with another biotinylated reagent, subsequent application of streptavidin-APC resulted in high non-specific APC staining. This could be avoided by staining with CD33 PE after all other staining steps have been completed.
  • S***s2023-01-12
    0사람들이 좋아합니다
    We purchased this antibody to use for flow cytometry on a client study, who specifically requested Acro antibodies! They are reliable and have continued to be one of our top providers of antibodies. We typically use multiple fluorescent antibodies with various protein targets and fluorophores at once for flow cytometry panels in human and mouse tissues, and Acro antibodies have always given us a great readout.
  • 분자 정보
  • 제품 목록
  • 시판 약물 정보
  • 제품 리뷰
  • 임상 약물 정보
문의하기

전화
글로벌: +1 800-810-0816 (무료)
아시아태평양: +86 400-682-2521

주소 서울특별시 송파구 법원로11길 11, 제3층 제비-314,315호